Trial
NCT04294160
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
BRAF V600 Colorectal Cancer
Intervention
Dabrafenib
Why stopped
The decision of early termination was made due to business reasons, and was not based on any safety concerns for any of the treatment combinations.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-24